Previous 10 | Next 10 |
Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechno...
H.C. Wainwright has initiated GeoVax Labs ( NASDAQ: GOVX ) with a buy highlighting its pipeline of cancer immunotherapy and infectious diseases candidates. The firm has an $8 price target (~820% upside based on Tuesday's close). Shares are up 16% in Thursday mornin...
ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial ...
Presentation to Focus on Development of Pan-Coronavirus (Universal) Vaccines to Protect Against Evolving Variants Atlanta, GA - ( NewMediaWire ) - October 11, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapi...
ATLANTA, GA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the Midcap Ro...
3 Trending Penny Stocks to Add to Your Watchlist Right Now For many people, the answer to whether penny stocks are worth investing in or not is tricky. The stock market is currently in a state of flux, with prices fluctuating rapidly and unpredictably. Many experts believe that we are o...
3 Tips for Finding Penny Stocks to Buy in September If you’re thinking about buying penny stocks, there are a few things you should know. First, the stock market is volatile, so prices can go up and down quickly. Second, penny stocks can be either a long-term or short-term in...
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin ® ) Atlanta, GA - ( NewMediaWire ) - September 07, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company spe...
Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board ATLANTA, GA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious dise...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GeoVax Labs (NASDAQ: GOVX ) recently released its second-quarter 2022 financial results . Some investors might object to GeoVax’s net earnings loss. However, there’s still upside potential for GOVX stoc...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...